Drugs / Allogeneic CD19 CR-T cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05143112 | Feb 2021 → Feb 2024 | B-cell non-Hodgkin lymphoma | Shenzhen University General Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic CD19 CR-T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05143112 ↗ |
| Action | Deplete | “recognize and kill tumor cells that express specific antigens” NCT05143112 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor (CAR) T cells enable T cells to recognize and kill tumor cells” NCT05143112 ↗ |